Specific shRNA of human fibrinogen single chain, recombinant interference vector and its application
By designing a single-stranded shRNA and recombinant interference vector of human fibrinogen, stably interfering with fibrinogen expression in tumor cells, the problem of difficulty in improving tumor sensitivity to chemotherapy and targeted drugs in the prior art is solved, and the difference is achieved Significant sensitivity to tumor type is enhanced.
Patent Information
- Application Number
- CN202010490529.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2020-06-02
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2040-06-02
AI Technical Summary
The prior art is difficult to specifically reduce the expression level of fibrinogen single strand in tumor cells, thereby improving the sensitivity of tumors to chemotherapy and targeted drugs, especially when different tumor cells express uneven levels of FGA, FGB and FGG.
Design and construct specific shRNAs of single-stranded human fibrinogen, and lentiviral packaging is carried out through recombinant interference vectors (such as pLKO.1-shFGA/FGB/FGG), stabilizing fibrinogen expression in tumor cells, enhancing chemotherapy and targeting Drug sensitivity.
By specifically reducing fibrinogen levels, the sensitivity of different tumor cells (such as kidney, ovarian, breast, liver, colon, nasopharyngeal, gastric or lung cancer) to chemotherapy and targeted drugs has been significantly improved. It provides an important target to enhance the sensitivity of traditional tumor treatments.
Smart Images

Figure CN111647601B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biotechnology and relates to specific shRNA of human fibrinogen single chain, a recombinant interference vector and application. Background Art
[0002] Human fibrinogen, also known as human coagulation factor I, is a polymer peptide composed of two protein trimers, which is composed of two groups of Aα, Bβ and γ protein peptide chains connected by 29 disulfide bonds. The three single-chain proteins are transcribed by independent mRNAs, and the related genes are all located on the long arm of chromosome 4, q23-q32, with a total length of 50kb, which is a group of discontinuous single copy genes. Fibrinogen is a large molecular glycoprotein that is released to the periphery of cells through cell secretion. Tumor patients, especially those with advanced tumors, often present with hyperfibrinogenemia. The applicant's previous basic research found that ectopic expression of tumor cells is an important source of plasma fibrinogen. However, the expression of fibrinogen single chains by tumor cells showed a significant imbalance, indicating that different single chains have different effects on the progression of tumors.
[0003] As an important component of the tumor microenvironment, fibrinogen plays an important role in tumor progression. By searching Medline, EMBASE, and Cochrane literature, the effects of plasma fibrinogen on tumor treatment were summarized, analyzed, and evaluated. Data from 52 previously reported observational studies and 15,371 patients showed that high plasma fibrinogen was associated with poor prognosis in the treatment of various tumors, including renal cell carcinoma, head and neck cancer, colorectal cancer, breast cancer, pancreatic cancer, ovarian cancer, and non-small cell lung cancer. Theoretical studies speculate that fibrinogen participates in the occurrence and development of tumors in various ways, such as affecting drug diffusion, inducing tumor cell dormancy, blocking tumor antigens, and regulating signal transduction. However, the relevant molecular mechanisms are still in preliminary research.
[0004] Molecular biology techniques can specifically knock down the expression level of a gene. Interfering RNA (siRNA) can specifically block the transcriptional expression level of each single strand of fibrinogen. By further constructing lentivirus, the transfection efficiency of tumor cells can be further improved. However, due to the uneven expression of FGA, FGB and FGG levels in different tumor cells, their biological functions also vary among tumor types. Whether siRNA can be used to reduce the level of specific fibrinogen single strands to achieve the purpose of improving the therapeutic effect of tumors has not been reported yet. Summary of the invention
[0005] In view of this, the object of the present invention is to provide a human fibrinogen single-chain specific shRNA, a recombinant interference vector and its application.
[0006] In order to achieve the above object, the present invention provides the following technical solutions:
[0007] 1. Specific shRNA for human fibrinogen single chain, including:
[0008] (1)shFGA:
[0009] Top: 5'- CCGGGGAAGGCATTAACAGACATGCTTCAAGAGAGCATGTCTGTTAATGCCTTCCTTTTTTT GGTACC-3', as shown in SEQ ID NO.1;
[0010] Bottom: 5'- AATTGGTACCAAAAAAGGAAGGCATTAACAGACATGCTCTCTTGAAGCATGTCTGTTAA TGCCTTCC-3', as shown in SEQ ID NO.2;
[0011] (2)shFGB:
[0012] Top:
[0013] 5'-CCGGGCACTGTCAGTTGCAATATTCTTCAAGAGAGAATATTGCAACTGACAGTGCTTTTTTGGTACC-3', as shown in SEQ ID NO.3;
[0014] Bottom:
[0015] 5'- AATTGGTACCAAAAAAGCACTGTCAGTTGCAATATTCTCTCTTGAAGAATATTGCAACTGACAGTGC-3', as shown in SEQ ID NO.4;
[0016] (3)shFGG:
[0017] Top:
[0018] 5'-CCGGGCATCTTAGATGAAAGATTCGTTCAAGAGACGAATCTTTCATCTAAGATGC TTTTTTGGTACC-3', as shown in SEQ ID NO.5;
[0019] Bottom:
[0020] 5′- AATTGGTACCAAAAAAGCATCTTAGATGAAAGATTCGTCTCTTGAACGAATCTTTCATCTAAGATGC-3′, as shown in SEQ ID NO.6.
[0021] 2. The human fibrinogen interference sequence shFGA / FGB / FGG was constructed using the above-mentioned human fibrinogen single-strand specific shRNA.
[0022] 3. The recombinant interference vector was constructed using the above-mentioned human fibrinogen single-chain specific shRNA.
[0023] 4. The method for constructing the above-mentioned recombinant interference vector is as follows: the human fibrinogen interference sequence shFGA / FGB / FGG obtained by constructing the above-mentioned human fibrinogen single-strand specific shRNA is connected with the pLKO.1 plasmid which is linearly cut by AgeI and EcoRI restriction endonucleases to obtain the recombinant interference vector pLKO.1-shFGA / FGB / FGG.
[0024] Preferably, T4 ligase is used for ligation.
[0025] 5. Use of the above-mentioned human fibrinogen single-chain specific shRNA or recombinant interference vector in the preparation of anti-tumor drugs for reducing human fibrinogen gene expression.
[0026] Preferably, the tumor is selected from any one of renal cancer, ovarian cancer, breast cancer, liver cancer, colon cancer, nasopharyngeal cancer, gastric cancer or lung cancer.
[0027] 6. Use of the above-mentioned human fibrinogen single-chain specific shRNA or recombinant interference vector in the preparation of drugs for enhancing the sensitivity of anti-tumor chemotherapy drugs or targeted drugs.
[0028] Preferably, the tumor is selected from any one of renal cancer, ovarian cancer, breast cancer, liver cancer, colon cancer, nasopharyngeal cancer, gastric cancer or lung cancer.
[0029] Preferably, the active ingredient of the anti-tumor chemotherapy drug is selected from any one of doxorubicin, paclitaxel, trastuzumab, sorafenib, 5-fluorouracil, cisplatin, vincristine or gefitinib.
[0030] The beneficial effects of the present invention are:
[0031] The present invention designs specific interfering RNA and a recombinant interfering vector expressing the shRNA for each single strand of human fibrinogen, transfects tumor cells, knocks down the fibrinogen expression of tumor cells, and enhances the sensitivity of tumors to chemotherapy and targeted drugs.
[0032] The human fibrinogen shRNA of the present invention can specifically reduce the level of fibrinogen. By constructing a shRNA recombinant interference vector and packaging it with a lentivirus, it can stably interfere with the fibrinogen expression of tumor cells. Experiments have shown that single-chain fibrinogen knockdown can enhance the therapeutic sensitivity of different tumor types (renal cancer, ovarian cancer, breast cancer, liver cancer, colon cancer, nasopharyngeal cancer, gastric cancer or lung cancer), and is an important target for enhancing the sensitivity of traditional tumor treatment. BRIEF DESCRIPTION OF THE DRAWINGS
[0033] In order to make the purpose, technical solution and beneficial effects of the present invention clearer, the present invention provides the following drawings for illustration:
[0034] Figure 1 Schematic diagram of the construction of shFGA, shFGB and shFGG plasmids, wherein a is shFGA, b is shFGB, c is shFGG, and d is pLKO.1 plasmid;
[0035] Figure 2 The identification of drug resistance of spheroid tumor cells, where a~h are the drug resistance identification results to doxorubicin, cisplatin, 5-fluorouracil, paclitaxel, vincristine, trastuzumab, gefitinib and sorafenib respectively;
[0036] Figure 3 Real-time PCR verification of down-regulation of fibrinogen single chain expression in tumor spheroid cells infected with lentivirus, where a to c are the verification results of shFGA, shFGB and shFGG respectively;
[0037] Figure 4 Figure 3 shows the changes in drug resistance of different tumor cells after knocking down FGA, FGB and FGG. a to h are the drug resistance results to doxorubicin, cisplatin, 5-fluorouracil, paclitaxel, vincristine, trastuzumab, gefitinib and sorafenib after knocking down the genes. DETAILED DESCRIPTION
[0038] The preferred embodiments of the present invention will be described in detail below with reference to the accompanying drawings.
[0039] Specific experimental methods not specified in the examples were performed according to conventional experimental conditions, with reference to the experimental protocols described in "A Guide to Molecular Cloning (3rd Edition, by J. Sambrook et al.)" or the conditions recommended by the manufacturer.
[0040] 1. Obtaining specific interference sequences of each single chain (FGA, FGB and FGG) of human fibrinogen:
[0041] The siRNA sequences were designed based on the single-stranded sequences of human fibrinogen published by NCBI (FGA, NM_000508.5; FGB, NM_005141.5; FGG, NM_000509.5). The specific design method was to use the RNAi online design tool on the Life Technologies website ( https: / / rnaidesigner.thermofisher.com / rnaiexpress / sort.do ) Design interference target sequence based on human fibrinogen single-chain gene sequence:
[0042] (FGA: 5'-GGAAGGCATTAACAGACATGC-3'; FGB: 5'-GCACTGTCAGTTGCAATATTC-3'; FGG: 5'-GCATCTTAGATGAAAGATTCG-3').
[0043] According to the designed sequence, the shRNA sequences were constructed as follows:
[0044] shFGA:
[0045] Top 5'-CCGG GGAAGGCATTAACAGACATGC TTCAAGAGAGCATGTCTGTTAATGCCTTCC TTTTTTTGGTACC-3';
[0046] Bottom 5'- AATTGGTACCAAAAAAGGAAGGCATTAACAGACATGCTCTCTTGAA GCATGTCTGTT AATGCCTTCC -3';
[0047] shFGB:
[0048] Top
[0049] 5'-CCGG GCACTGTCAGTTGCAATATTC TTCAAGAGAGAATATTGCAACTGACAGTGCTTTTTTGGTACC-3';
[0050] Bottom
[0051] 5'- AATTGGTACCAAAAAAGCACTGTCAGTTGCAATATTCTCTCTTGAA GAATATTGCAACTGACAG TGC -3'.
[0052] shFGG:
[0053] Top
[0054] 5'-CCGG GCATCTTAGATGAAAGATTCGTTCAAGAGACGAATCTTTCATCTAAGATGC TTTTTTGGTACC-3';
[0055] Bottom
[0056] 5'- AATTGGTACCAAAAAAGCATCTTAGATGAAAGATTCGTCTCTTGAA CGAATCTTTCATCTAAGA TGC -3'
[0057] Anneal each set of sequences to construct a double-stranded structure. Specifically, prepare a 50 μM synthetic sequence solution, take 4.5 μl of each, add 1 μl of annealing buffer, and prepare a 10 μl reaction system. Run the following program on the PCR instrument: 95°C for 4 minutes (melting), 75°C for 10 minutes (annealing), to form an annealed double-stranded sequence, such as Figure 1 As shown, a is shFGA, b is shFGB, and c is shFGG.
[0058] 2. Construction of recombinant interference vector:
[0059] Prepare the pLKO.1 plasmid (eg, Figure 1 As shown in Figure d, pLKO.1 plasmid was donated by Addgene, #8453). Take 1 μl of annealed sequence and 50 ng of linear pLKO.1 plasmid, and connect them to the pLKO.1 vector using T4 ligase (purchased from New England Biolabs) to obtain the recombinant interference vector pLKO.1-shFGA / FGB / FGG. The plasmids were transformed into DH5α competent cells, and the plasmids were extracted after amplification. The diluted plasmid concentration was 1000 ng / μl.
[0060] 3. Lentivirus packaging:
[0061] HEK293 cells (purchased from ATCC) were cultured in 10 cm culture dishes. When the cells were growing well, 9 ml Opti-MEM medium was replaced. Four 2 ml EP tubes were prepared, and 10 μg of pLKO.1 blank or recombinant interference plasmid, 6.5 μg of DR8.9 packaging plasmid (gift from Addgene), and 3.5 μg of VSVG plasmid (gift from Addgene) were added to each tube. Opti-MEM medium was added to 500 μl and mixed. Also 200 μl of Trans-EZ (purchased from Shanghai Shengbo) and 1.8 ml of Opti-MEM medium were prepared. After mixing, 500 μl was added to the plasmid tube and mixed at room temperature for 20 minutes. 1 ml of mixed plasmid was added to the HEK293 cell culture dish. After 6 hours, it was replaced with 10 ml of DMEM complete medium. After 48 hours of culture, the supernatant of the culture medium was collected and filtered with a 0.22 μm PVDF filter to obtain the corresponding lentivirus.
[0062] 4. Continuous spheroid subculture to enrich tumor stem cells:
[0063] The total number is 1*10 6 The human renal cancer cell line Caki-1, nasopharyngeal cancer cell line CNE2, colon cancer cell line SW480, ovarian cancer cell line SK-OV-3, gastric cancer cell line SGC7901, breast cancer cell line SKBR3, lung cancer cell line A549, and liver cancer cell line HepG2 (all purchased from ATCC) were inoculated into low-adhesion 6-well plates and suspended in DF12 stem cell culture medium. After 10 days of cell culture, cell spheres with more than 50 cells can be observed. Tumor cell spheres were collected by centrifugation, lysed into single cells by trypsin, and then serially passaged and suspended in DF12 stem cell culture medium. The cells were subcultured once every 10 days, and the culture time was maintained for at least 3 months.
[0064] 5. Identification of drug resistance of continuously passaged spheroid cells:
[0065] 5000 corresponding spheroid cells and parental cells were inoculated into 96-well plates, and 5 replicate wells were set. After the cells adhered to the wall, gradient concentrations of doxorubicin (0.01, 0.05, 0.1, 0.5, 1, 5, 10, 50, 100, 200 μg / ml) were used to treat renal cancer cells Caki-1, cisplatin (0.01, 0.05, 0.1, 0.5, 1, 5, 10, 50, 100, 200 μg / ml) was used to treat nasopharyngeal cancer cells CNE2, 5-fluorouracil (0.01, 0.05, 0.1, 0.5, 1, 5, 10, 50, 100, 200, 500 μg / ml) was used to treat colon cancer cells SW480, and paclitaxel (0.01, 0.05, 0.1, 0.5, 1, 5, 10, 50 μg / ml) was used to treat ovarian cancer cells. Cancer cell SK-OV-3 cells, gastric cancer cell SGC7901 treated with vincristine (0.01, 0.05, 0.1, 0.5, 1, 5, 10, 50, 100, 200 μg / ml), breast cancer cell SKBR3 treated with trastuzumab (0.01, 0.05, 0.1, 0.5, 1, 5, 10, 50, 100 μg / ml), lung cancer cell A549 treated with gefitinib (0.01, 0.05, 0.1, 0.5, 1, 5, 10, 50, 100 μM), liver cancer cell HepG2 treated with sorafenib (0.01, 0.05, 0.1, 0.5, 1, 5, 10, 50, 100, 200 μM). After 48 hours of cell culture, the cell proliferation inhibition ratio was detected using the Cell Counting Kit-8 kit (purchased from Shanghai Biotech). Specifically, 10 μl of CCK-8 solution was added to each well and incubated in the cell culture incubator for 60 minutes. The absorbance at 450 nm was detected using an ELISA reader. The cell proliferation inhibition rate was calculated as (1-absorbance of the experimental group / absorbance of the control group)*100%. The independent experiment was repeated three times. The IC50 values of each group of cells were calculated respectively. The spheroid cells showed significant cell resistance ( Figure 2 , a~h are the drug resistance identification results to doxorubicin, cisplatin, 5-fluorouracil, paclitaxel, vincristine, trastuzumab, gefitinib and sorafenib, respectively).
[0066] 6. Lentivirus was used to transfect tumor spheroid cells to obtain a tumor cell line with stable downregulated expression of single-chain fibrinogen, and its transfection interference efficiency was verified.
[0067] Renal cancer cell line Caki-1, nasopharyngeal cancer cell line CNE2, lung cancer cell line A549, colon cancer cell line SW480, breast cancer anthracycline-resistant cell line SKBR3, and ovarian cancer cell line SK-OV-3 were treated with shRNA-containing lentivirus for 72 hours. The transfected cells were collected and mRNA was extracted to detect the expression levels of each single chain of tumor cell fibrinogen. RT-qPCR results showed that with the increase of drug concentration, the transcription level of tumor cell fibrinogen decreased significantly ( Figure 3 , a~c are the verification results of shFGA, shFGB and shFGG respectively).
[0068] 7. Detect changes in drug sensitivity of FGA, FGB, and FGG knockdown tumor cell lines:
[0069] The applicant used gradient concentrations of drugs to treat related tumor cells, including doxorubicin (0.01, 0.05, 0.1, 0.5, 1, 5, 10, 50, 100, 200 μg / ml) for treating renal cancer cell Caki-1, cisplatin (0.01, 0.05, 0.1, 0.5, 1, 5, 10, 50, 100, 200 μg / ml) for treating nasopharyngeal cancer cell CNE2, 5-fluorouracil (0.01, 0.05, 0.1, 0.5, 1, 5, 10, 50, 100, 200, 500 μg / ml) for treating colon cancer cell SW480, and paclitaxel (0.01, 0.05, 0.1, 0.5, 1, 5, 10, 50, 100, 200 μg / ml) for treating nasopharyngeal cancer cell CNE2. 10, 50 μg / ml) for treating ovarian cancer cells SK-OV-3, vincristine (0.01, 0.05, 0.1, 0.5, 1, 5, 10, 50, 100, 200 μg / ml) for treating gastric cancer cells SGC7901, trastuzumab (0.01, 0.05, 0.1, 0.5, 1, 5, 10, 50, 100 μg / ml) for treating breast cancer cells SKBR3, gefitinib (0.01, 0.05, 0.1, 0.5, 1, 5, 10, 50, 100 μM) for treating lung cancer cells A549, sorafenib (0.01, 0.05, 0.1, 0.5, 1, 5, 10, 50, 100, 200μM) were used to treat the liver cancer cells HepG2, and the control group and the fibrinogen single chain knockdown cells were treated for 48 hours. The cell proliferation after treatment was compared, and the IC50 values of the cells were calculated (mean ± SD). The results showed that FGA, FGB or FGG knockdown showed significantly enhanced sensitivity to tumor chemotherapy and targeted therapy in different tumor cells ( Figure 4 , a~h are the drug resistance results to doxorubicin, cisplatin, 5-fluorouracil, paclitaxel, vincristine, trastuzumab, gefitinib and sorafenib after gene knockdown, respectively).
[0070] The results showed that knocking down FGA had a significant sensitizing effect on the following tumors: renal cancer cell line Caki-1, ovarian cancer cell line SKOV-3 cells, breast cancer SKBR3, and liver cancer cell line HepG2; knocking down FGB had a significant sensitizing effect on the following tumors: colon cancer cell line SW480, breast cancer SKBR3, and liver cancer cell line HepG2; knocking down FGG had a significant sensitizing effect on the following tumors: nasopharyngeal cancer cell line CNE2, ovarian cancer cell line SKOV-3 cells, gastric cancer cell line SGC7901, and lung cancer cell line A549.
[0071] Finally, it should be noted that the above preferred embodiments are only used to illustrate the technical solutions of the present invention rather than to limit it. Although the present invention has been described in detail through the above preferred embodiments, those skilled in the art should understand that various changes can be made in form and details without departing from the scope defined by the claims of the present invention. Sequence Listing <110> Liu Yulin <120> Specific shRNA of human fibrinogen single chain, recombinant interference vector and its application <130> 2020 <160> 6 <170> SIPOSequenceListing 1.0 <210> 1 <211> 67 <212> DNA <213> Artificial <400> 1 ccggggaagg cattaacaga catgcttcaa gagagcatgt ctgttaatgc cttccttttt 60 tggtacc 67 <210> 2 <211> 67 <212> DNA <213> Artificial <400> 2 aattggtacc aaaaaaggaa ggcattaaca gacatgctct cttgaagcat gtctgttaat 60 gccttcc 67 <210> 3 <211> 67 <212> DNA <213> Artificial <400> 3 ccgggcactg tcagttgcaa tattcttcaa gagagaatat tgcaactgac agtgcttttt 60 tggtacc 67 <210> 4 <211> 67 <212> DNA <213> Artificial <400> 4 aattggtacc aaaaaagcac tgtcagttgc aatattctct cttgaagaat attgcaactg 60 acagtgc 67 <210> 5 <211> 67 <212> DNA <213> Artificial <400> 5 ccgggcatct tagatgaaag attcgttcaa gagacgaatc tttcatctaa gatgcttttt 60 tggtacc 67 <210> 6 <211> 67 <212> DNA <213> Artificial <400> 6 aattggtacc aaaaaagcat cttagatgaa agattcgtct cttgaacgaa tctttcatct 60 aagatgc 67
Claims
1. A single-stranded human fibrinogen specific shRNA, characterized in that: The specific shRNA comprises: (1) shFGA: Top: 5'-CCGGGGAAGGCATTAACAGACATGCTTCAAGAGAGCATGTCTGTTAATGCCTTCC TTTTTT GGTACC-3', as shown in SEQ ID NO.1; Bottom: 5'-AATTGGTACCAAAAAAGGAAGGCATTAACAGACATGCTCTCTTGAAGCATGTCTGTTAATGCCTTCC-3', as shown in SEQ ID NO.2; (2) shFGB: Top: 5'-CCGGGCACTGTCAGTTGCAATATTCTTCAAGAGAGAATATTGCAACTGACAGTGCTTTTTTGGTACC-3', as shown in SEQ ID NO.3; Bottom: 5'-AATTGGTACCAAAAAAGCACTGTCAGTTGCAATATTCTCTCTTGAAGAATATTGCAACTGACAGTGC -3', as shown in SEQ ID NO.4; (3) shFGG: Top: 5'-CCGGGCATCTTAGATGAAAGATTCGTTCAAGAGACGAATCTTTCATCTAAGATGC TTTTTT GGTACC-3', as shown in SEQ ID NO.5; Bottom: 5′-AATTGGTACCAAAAAAGCATCTTAGATGAAAGATTCGTCTCTTGAACGAATCTTTCATCTAAGATGC -3′, as shown in SEQ ID NO.
6.
2. The human fibrinogen interference sequence shFGA / FGB / FGG constructed using the human fibrinogen single-strand specific shRNA of claim 1.
3. A recombinant interference vector constructed using the specific shRNA of the human fibrinogen single chain as described in claim 1.
4. The recombinant interference vector according to claim 3, characterized in that: The specific construction method is as follows: the human fibrinogen interference sequence shFGA / FGB / FGG obtained by constructing the above-mentioned human fibrinogen single-chain specific shRNA is connected with the pLKO.1 plasmid cut into a linear form by AgeI and EcoRI restriction endonucleases to obtain the recombinant interference vector pLKO.1-shFGA / FGB / FGG.
Citation Information
Patent Citations
Serum and tissue biomarkers of human hcc
US20130078255A1
Method of judging senstivity of tumor cell to anticancer agent
WO2005007846A1
